title: The influence of Helicobacter pylori eradication on leptin, soluble CD40 ligand, oxidative stress and body composition in patients with peptic ulcer disease.
abstract: OBJECTIVE
  To determine the effect of Helicobacter pylori (H. pylori) eradication on blood levels of soluble CD40 ligand, leptin, oxidative stress and body composition in patients with dyspepsia infected with H. pylori.
  
  
  METHODS
  The infection of H. pylori was based on the presence of both (14)C urea breath test (UBT) and histology. Patients were given triple eradication therapy for 14 days and at 3 months after the treatment, (14)C UBT was reinstituted. Fasting glucose, leptin, body composition, soluble CD40 ligand, total oxidant status (TOS) were studied before and at 3 months after the treatment.
  
  
  RESULTS
  In 33 subjects, H. pylori infection was successfully eradicated. sCD40L, and TOS levels were significantly decreased after H. pylori eradication. The percentage of body fat and body fat mass significantly decreased whereas the fat free mass (FFM) increased after eradication. However, eradication of the organism yielded no differences in leptin levels.
  
  
  CONCLUSIONS
  These findings suggest that H. pylori eradication reduces the sCD40L and oxidative stress, fat mass with a significant increase in fat free mass. Thus, eradication of H. pylori infection not only improves ulcer healing, but may also reduce the presumed atherosclerosis risk.
authors.affiliation: Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey. leventkebapcilar@yahoo.com
authors.forename: Levent
authors.initials: L
authors.lastname: Kebapcilar
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
authors.forename: Ali Haydar
authors.initials: AH
authors.lastname: Renkal
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: Arif
authors.initials: A
authors.lastname: Yuksel
authors.forename: Enver
authors.initials: E
authors.lastname: Ilhan
authors.forename: Bulent
authors.initials: B
authors.lastname: Alkan
authors.forename: Diydem
authors.initials: D
authors.lastname: Yuksel
authors.forename: Didem L
authors.initials: DL
authors.lastname: Kozaci
authors.forename: Necati
authors.initials: N
authors.lastname: Gunay
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D050197:Atherosclerosis; D050218:Body Fat Distribution; D023201:CD40 Ligand / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000097:blood* / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D020738:Leptin / Q000097:blood; D008297:Male; D018384:Oxidative Stress; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy / Q000382:microbiology*; D011446:Prospective Studies; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D020738:Leptin; D023201:CD40 Ligand